Modulation of semaphorin 3C & 4D expression in cancerous tissues from individuals with laryngeal squamous cell carcinoma.
Journal
The Indian journal of medical research
ISSN: 0971-5916
Titre abrégé: Indian J Med Res
Pays: India
ID NLM: 0374701
Informations de publication
Date de publication:
01 Oct 2023
01 Oct 2023
Historique:
received:
27
10
2021
medline:
27
11
2023
pubmed:
26
11
2023
entrez:
25
11
2023
Statut:
ppublish
Résumé
Semaphorins were initially characterized as axon guidance factors but were subsequently implicated in the regulation of immune responses, angiogenesis, organ formation and a variety of other physiological and developmental functions. Various semaphorins enhance or inhibit tumour progression through different mechanisms. The objective of this study was to assess the expression of various semaphorins and vascular endothelial growth factor (VEGF) gene transcripts as well as the serum level of Sema3A in individuals with laryngeal squamous cell carcinoma (LSCC). Tissue expression of Sema3A, Sema3C, Sema4D, Sema6D and VEGF was determined in both tumour tissues and tissues around the tumour from 30 individuals with pathologically confirmed LSCC using quantitative real-time PCR. Furthermore, the serum level of Sema3A in these individuals was assessed using enzyme-linked immunosorbent assay. Sema3C gene transcript showed a significant increase (P=0.001), while Sema4D was observed with a significant decrease in tumour samples compared to non-tumoural tissues (P≤0.01). The expression of the Sema3C gene was found to be associated with the stage of LSCC tumour as it was statistically significant for tumours with stage IV (P<0.01). The serum level of Sema3A was not found to be significant between cases and controls. Increased expression of Sema3C but decreased expression of Sema4D in tumour tissue of LSCC may introduce these two growth factors as crucial mediators orchestrating tumour growth in individuals with LSCC. This result could open a new vision for the treatment of this malignancy.
Sections du résumé
BACKGROUND OBJECTIVES
UNASSIGNED
Semaphorins were initially characterized as axon guidance factors but were subsequently implicated in the regulation of immune responses, angiogenesis, organ formation and a variety of other physiological and developmental functions. Various semaphorins enhance or inhibit tumour progression through different mechanisms. The objective of this study was to assess the expression of various semaphorins and vascular endothelial growth factor (VEGF) gene transcripts as well as the serum level of Sema3A in individuals with laryngeal squamous cell carcinoma (LSCC).
METHODS
METHODS
Tissue expression of Sema3A, Sema3C, Sema4D, Sema6D and VEGF was determined in both tumour tissues and tissues around the tumour from 30 individuals with pathologically confirmed LSCC using quantitative real-time PCR. Furthermore, the serum level of Sema3A in these individuals was assessed using enzyme-linked immunosorbent assay.
RESULTS
RESULTS
Sema3C gene transcript showed a significant increase (P=0.001), while Sema4D was observed with a significant decrease in tumour samples compared to non-tumoural tissues (P≤0.01). The expression of the Sema3C gene was found to be associated with the stage of LSCC tumour as it was statistically significant for tumours with stage IV (P<0.01). The serum level of Sema3A was not found to be significant between cases and controls.
INTERPRETATION CONCLUSIONS
UNASSIGNED
Increased expression of Sema3C but decreased expression of Sema4D in tumour tissue of LSCC may introduce these two growth factors as crucial mediators orchestrating tumour growth in individuals with LSCC. This result could open a new vision for the treatment of this malignancy.
Identifiants
pubmed: 38006346
doi: 10.4103/ijmr.ijmr_3148_21
pii: 02223309-202310000-00015
doi:
Substances chimiques
Semaphorin-3A
0
Vascular Endothelial Growth Factor A
0
Semaphorins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
432-438Informations de copyright
Copyright © 2023 Copyright: © 2023 Indian Journal of Medical Research.
Références
Ferreira GD, Capp E, Jauckus J, Strowitzki T, Germeyer A. Expression of semaphorin class 3 is higher in the proliferative phase on the human endometrium. Arch Gynecol Obstet 2018; 297: 1175–9.
Ma Y, Fang M, Zhou X. Semaphorin 3B gene suppresses tumor growth through the p53 signaling pathway and neuropilin receptors. Am J Clin Exp Med 2017; 5: 234–8.
Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, et al. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Eur J Cancer 2018; 91: 47–55.
Domingueti CB, Janini JB, Paranaíba LM, Lozano-Burgos C, Olivero P, González-Arriagada WA. Prognostic value of immunoexpression of CCR4, CCR5, CCR7 and CXCR4 in squamous cell carcinoma of tongue and floor of the mouth. Med Oral Patol Oral Cir Bucal 2019; 24: e354–63.
Swiecicki PL, Brennan JR, Mierzwa M, Spector ME, Brenner JC. Head and neck squamous cell carcinoma detection and surveillance:Advances of liquid biomarkers. Laryngoscope 2019; 129: 1836–43.
Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines 2017; 5: 34.
Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis:a crucial target for anti-and pro-angiogenic therapies. Genes &cancer 2011; 2 (12): 1097–105.
Toledano S, Nir-Zvi I, Engelman R, Kessler O, Neufeld G. Class-3 semaphorins and their receptors:potent multifunctional modulators of tumor progression. Int J mol Sci 2019; 20 (3): 556.
Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer:Reassessing the target. Cancer Res 2012; 72: 1909–14.
Neufeld G, Mumblat Y, Smolkin T, Toledano S, Nir-Zvi I, Ziv K, et al. The semaphorins and their receptors as modulators of tumor progression. Drug Resist Updat 2016; 29: 1–12.
Neufeld G, Sabag AD, Rabinovicz N, Kessler O. Semaphorins in angiogenesis and tumor progression. Cold Spring Harb Perspect Med 2012; 2: a006718.
Mansourabadi Z, Razmkhah M, Mohtasebi MS, Talei AR, Ghaderi A. Expression of major histocompatibility complex class I polypeptide-related sequence B in adipose-derived stem cells from breast cancer patients and normal individuals. J Cancer Res Ther 2019; 15: 1067–72.
Neufeld G, Mumblat Y, Smolkin T, Toledano S, Nir-Zvi I, Ziv K, et al. The role of the semaphorins in cancer. Cell Adh Migr 2016; 10: 652–74.
Granziero L, Circosta P, Scielzo C, Frisaldi E, Stella S, Geuna M, et al. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+B lymphocytes. Blood 2003; 101: 1962–9.
Parsa S, Sharifzadeh S, Monabati A, Seyyedi N, Ranjbaran R, Baghbani MR, et al. Overexpression of semaphorin-3A and semaphorin-4D in the peripheral blood from newly diagnosed patients with chronic lymphocytic leukemia. Int J Hematol Oncol Stem Cell Res 2019; 13: 25–34.
Kato S, Kubota K, Shimamura T, Shinohara Y, Kobayashi N, Watanabe S, et al. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci 2011; 102: 2029–37.
Liu H, Yang Y, Xiao J, Yang S, Liu Y, Kang W, et al. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients. Microvasc Res 2014; 93: 1–8.
Chen D, Li Y, Wang L, Jiao K. SEMA6D expression and patient survival in breast invasive carcinoma. Int J Breast Cancer 2015; 2015: 539721.
Zhao XY, Chen L, Xu Q, Li YH. Expression of semaphorin 6D in gastric carcinoma and its significance. World J Gastroenterol 2006; 12: 7388–90.
Rajabinejad M, Asadi G, Ranjbar S, Afshar Hezarkhani L, Salari F, Gorgin Karaji A, et al. Semaphorin 4A, 4C, and 4D:Function comparison in the autoimmunity, allergy, and cancer. Gene 2020; 746: 144637.
He Y, Cheng Y, Huang Z, Xu W, Hu R, Cheng L, et al. A deep convolutional neural network-based method for laryngeal squamous cell carcinoma diagnosis. Ann Transl Med 2021; 9 1797.
Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath 2013; 3: 71–85.
Mishra R, Thorat D, Soundararajan G, Pradhan SJ, Chakraborty G, Lohite K, et al. Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis. Oncogene 2015; 34: 1584–95.
Li X, Chen Q, Yin D, Shi S, Yu L, Zhou S, et al. Novel role of semaphoring 3A in the growth and progression of hepatocellular carcinoma. Oncol Rep 2017; 37: 3313–20.
Bagci T, Wu JK, Pfannl R, Ilag LL, Jay DG. Autocrine semaphorin 3A signaling promotes glioblastoma dispersal. Oncogene 2009; 28: 3537–50.
Müller MW, Giese NA, Swiercz JM, Ceyhan GO, Esposito I, Hinz U, et al. Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int J Cancer 2007; 121: 2421–33.
Zhang D. SEMA3C supports pancreatic cancer progression by regulating the autophagy process and tumor immune microenvironment. Front Oncol .2022; 12: 890154.
Xu X, Zhao Z, Guo S, Li J, Liu S, You Y, et al. Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. Cancer Lett 2017; 397: 12–22.
Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, et al. SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol Med 2018; 10: 219–38.
Liu R, Shuai Y, Luo J, Zhang Z. SEMA3C promotes cervical cancer growth and is associated with poor prognosis. Front Oncol 2019; 9 1035.
Iragavarapu-Charyulu V, Wojcikiewicz E, Urdaneta A. Semaphorins in angiogenesis and autoimmune diseases:Therapeutic targets?. Front Immunol 2020; 11: 346.
Salimi-Sotoodeh M, Saffarian A, Taghipour M, Dehghanian AR, Chenari N, Ghaderi A, et al. Correlation of peritumoral edema and microvessel density with tissue expression of VEGF, semaphorins 3A and 3C in patients with meningioma. Asian Pac J Cancer Biol 2018; 3: 93–8.
Zou T, Dissanayaka WL, Jiang S, Wang S, Heng BC, Huang X, et al. Semaphorin 4D enhances angiogenic potential and suppresses osteo-/odontogenic differentiation of human dental pulp stem cells. J Endod 2017; 43: 297–305.
Zhang Y, Liu B, Ma Y, Jin B. Sema 4D/CD100-plexin B is a multifunctional counter-receptor. Cell Mol Immunol 2013; 10: 978.
Jiang H, Chen C, Sun Q, Wu J, Qiu L, Gao C, et al. The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer. Onco Targets Ther 2016; 9: 5737–50.
Sakurai A, Doçi CL, Gutkind JS. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. Cell Res 2012; 22: 23–32.